Health Trials

AngioVac Aspiration Therapy Registry

ConditionsIntracardiac ThrombusIntracardiac MassIntravascular ThrombosisVegetation; HeartVegetation; EndocarditisVegetation on CatheterThrombus of Right AtriumThrombus of Right VentricleThrombus Inferior Vena CavaThrombus of Pacemaker ElectrodeEndocarditis InfectiveEndocarditis, BacterialThrombus of Pulmonary ArteryThrombus on Catheter
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCharite University, Berlin, Germany

About this trial

As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:

1. Quantify Real-World Safety: Composite adverse event rates across diverse populations and indications 2. Assess Effectiveness: Technical and clinical success rates stratified by indication 3. Identify Predictors: Clinical, procedural, and anatomical factors predicting success versus complications 4. Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:

* Indication-specific outcomes * Multivariable prediction models * Time-to-event analyses (30-day and 12-month mortality) 5. Establish Best Practices: Evidence-based recommendations for patient selection, procedural technique, and follow-up

Eligibility criteria

Qualifiers

Age ≥18 years at time of AngioVac procedure

Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period)

Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026)

Written informed consent OR documented waiver/exemption from ethics authority (per local regulations per GDPR)

Disqualifiers

Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as >20% missing data in core endpoint variables)

Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact)

Non-AngioVac procedures: Patients undergoing thrombus/vegetation removal by surgery or other percutaneous devices only (not AngioVac)

Trial design

Treatments tested in this trial

  • Retrospective analysis of assigned treatment

Treatment groups

No treatment groups listed

Sponsors and collaborators

Charite University, Berlin, Germany

Lead sponsor

Angiodynamics, Inc.

Collaborator

Deutsches Herzzentrum der Charité

Collaborator

Source ClinicalTrials.gov